BioNeex Interviews

Interview with CEO of SilkTech Biopharmaceuticals, Brian Lawrence, PhD

Apr 19, 2021

Clinical Stage

SilkTech Biopharmaceuticals is Minneapolis based biotech company developing silk-based anti-inflammatory biotherapeutics. Currently, its lead drug candidate, Amlisimod (SDP-4) is in Phase 2 clinical trial for Dry Eye Disease.

Tags and Keywords

Amlisimod (SDP-4)
Dry Eye Disease
Phase 2
Silk-Based Biotherapeutics